CIPLA
Back to Balance Sheet
|
CIPLA Last 5 Year Contingent Liabilities History
[Consolidated]
| Mar2026 | Mar2025 | Mar2024 | Mar2023 | Mar2022 | |
|---|---|---|---|---|---|
| Contingent Liabilities | ₹987 Cr | ₹936 Cr | ₹634 Cr | ₹567 Cr | ₹743 Cr |
What is the latest Contingent Liabilities ratio of CIPLA ?
| Year | Contingent Liabilities |
|---|---|
| Mar2026 | ₹987 Cr |
| Mar2025 | ₹936 Cr |
| Mar2024 | ₹634 Cr |
| Mar2023 | ₹567 Cr |
| Mar2022 | ₹743 Cr |
How is Contingent Liabilities of CIPLA Trending?
| Years | Contingent Liabilities | % Change | |
|---|---|---|---|
| Mar2026 | ₹987 Cr | 5.48 | |
| Mar2025 | ₹936 Cr | 47.65 | |
| Mar2024 | ₹634 Cr | 11.90 | |
| Mar2023 | ₹567 Cr | -23.73 | |
| Mar2022 | ₹743 Cr | - | |
Compare Contingent Liabilities of peers of CIPLA
| Peers & Returns | Market Capitalization | 1 Week | 1 Month | 1 Year | ||
| CIPLA | ₹115,721.4 Cr | -0.4% | 5.8% | -2.9% | Stock Analytics | |
| SUN PHARMACEUTICAL INDUSTRIES | ₹470,786.0 Cr | 0.5% | 6.8% | 16.3% | Stock Analytics | |
| DIVIS LABORATORIES | ₹194,590.0 Cr | 0.6% | 8.7% | 7.9% | Stock Analytics | |
| TORRENT PHARMACEUTICALS | ₹191,658.0 Cr | 0.4% | 13.8% | 46.9% | Stock Analytics | |
| MANKIND PHARMA | ₹106,460.0 Cr | 1.2% | 6.6% | -5% | Stock Analytics | |
| DR REDDYS LABORATORIES | ₹100,708.0 Cr | -1.9% | -5.1% | -2.2% | Stock Analytics | |
CIPLA Share Price vs Sensex
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
| CIPLA | -0.4% |
5.8% |
-2.9% |
| SENSEX | 0.5% |
0.1% |
-6.1% |
You may also like the below Video Courses